What alternative drug would you use for cardiac arrest if epinephrine is ineffective?

Correct Answer: A. Amiodarone

Amiodarone is the evidence-based second-line antiarrhythmic agent for refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) when epinephrine fails to restore perfusing rhythm. Per Indian ACLS guidelines and AHA 2020 recommendations, amiodarone 300 mg IV bolus is given after the first defibrillation attempt if the rhythm persists. Its mechanism combines Class I (sodium channel blockade), II (beta-blockade), III (potassium channel blockade/prolonged APD), and IV (calcium channel blockade) properties, making it effective in suppressing ectopic activity and stabilizing the myocardium during resuscitation. Amiodarone increases the fibrillation threshold and improves the success of defibrillation, particularly in prolonged arrests. Unlike epinephrine (which acts as a pure alpha-1 agonist to increase coronary perfusion pressure), amiodarone directly addresses the electrical instability of the arrested heart. In Indian cardiac arrest protocols, amiodarone is preferred over lidocaine due to superior outcomes in refractory VF/VT, as demonstrated in ARREST trial data. The drug is administered after the second defibrillation attempt if the first shock fails, making it the logical alternative when epinephrine alone proves insufficient.

Why the other options are wrong

B. Adenosine — Adenosine is a purine nucleoside used for terminating supraventricular tachycardia (SVT) by blocking AV nodal conduction, not for cardiac arrest. It causes transient asystole and is contraindicated in VF/VT because it does not increase defibrillation threshold and may worsen the arrest. NBE trap: students confuse adenosine's role in tachyarrhythmia management with cardiac arrest protocols. C. Atropine — Atropine is an anticholinergic used for symptomatic bradycardia and asystole (0.5–1 mg IV every 3–5 min, max 3 mg), not for refractory VF/VT. It has no role in defibrillation-resistant arrests and does not improve myocardial electrical stability. Its use in cardiac arrest is limited to asystole/PEA with bradycardia, not the shockable rhythms where amiodarone is indicated. D. Vasopressin — Vasopressin (40 IU IV) was previously used as an alternative vasopressor in cardiac arrest but has been removed from most modern ACLS guidelines (including Indian protocols) due to lack of superior outcomes compared to epinephrine. It is no longer recommended as a first-line or second-line agent, making it an outdated choice. NBE may include this to test knowledge of current guidelines.

High-Yield Facts

Mnemonics

ACLS Drug Sequence (Shockable Rhythms) Epinephrine (1st line) → Amiodarone (2nd line) → Defibrillate. Epinephrine every 3–5 min; amiodarone after 2nd defibrillation attempt if VF/VT persists. Amiodarone's 4 Classes All 4 classes: I (Na+ block), II (β-block), III (K+ block/APD ↑), IV (Ca²⁺ block). Remember: amiodarone = 'all-in-one' antiarrhythmic.

NBE Trap

NBE pairs adenosine with cardiac arrest to trap students who conflate tachyarrhythmia management (where adenosine excels) with arrest protocols (where it is contraindicated). Similarly, vasopressin is included to test whether candidates know it has been de-emphasized in modern guidelines.

Clinical Pearl

In Indian ICUs, when a patient remains in VF after the first shock and epinephrine, amiodarone 300 mg IV is immediately drawn up and given during the next cycle of chest compressions. This 'push-shock-push' approach has become standard in Indian cardiac arrest teams, significantly improving neurologically intact survival in witnessed arrests.

_Reference: Harrison Ch. 295 (Cardiac Arrest); KD Tripathi Ch. 24 (Antiarrhythmics); Indian ACLS Guidelines 2020_